Elaine W Yu1, Marlene Wewalka1, Su-Ann Ding1, Donald C Simonson1, Kathleen Foster1, Jens J Holst1, Ashley Vernon1, Allison B Goldfine1, Florencia Halperin1. 1. Endocrine Unit (E.W.Y.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114; Research Division (M.W., S.-A.D., K.F., A.B.G.), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215; Division of Endocrinology (D.C.S., A.B.G., F.H.), Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Novo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences (J.J.H.), University of Copenhagen, Denmark; and Center for Metabolic and Bariatric Surgery (A.V.), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Abstract
CONTEXT: Roux-en-Y gastric bypass (RYGB) leads to high-turnover bone loss, but little is known about skeletal effects of laparoscopic adjustable gastric banding (LAGB) or mechanisms underlying bone loss after bariatric surgery. OBJECTIVE: To evaluate effects of RYGB and LAGB on fasting and postprandial indices of bone remodeling. DESIGN AND SETTING: Ancillary investigation of a prospective study at 2 academic institutions. PARTICIPANTS: Obese adults aged 21-65 years with type 2 diabetes who underwent RYGB (n = 11) or LAGB (n = 8). OUTCOMES: Serum C-terminal telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP), and PTH were measured during a mixed meal tolerance test at baseline, 10 days and 1 year after surgery. Changes in 25-hydroxyvitamin D, polypeptide YY (PYY), glucagon-like peptide-1, glucose-dependent insulinotropic peptide, and insulin were also assessed. RESULTS: Fasting CTX increased 10 days after RYGB but not LAGB (+69 ± 23% vs +12±12%, P < .001), despite comparable weight loss at that time. By 1 year, fasting CTX and P1NP increased more after RYGB than LAGB (CTX +221 ± 60% vs +15 ± 6%, P<0.001; P1NP +93 ± 25% vs -9 ± 10%, P < .001) and weight loss was greater with RYGB. Changes in CTX were independent of PTH and 25-hydroxyvitamin D but were associated with increases in fasting PYY. Postprandial suppression of CTX was more pronounced after RYGB than LAGB at 10 days and 1 year postoperatively. CONCLUSIONS: RYGB is accompanied by early increases in fasting indices of bone remodeling, independent of weight loss or changes in PTH or 25-hydroxyvitamin D. LAGB did not affect bone markers. PYY and other enterohormonal signals may play a role in RYGB-specific skeletal changes.
CONTEXT: Roux-en-Y gastric bypass (RYGB) leads to high-turnover bone loss, but little is known about skeletal effects of laparoscopic adjustable gastric banding (LAGB) or mechanisms underlying bone loss after bariatric surgery. OBJECTIVE: To evaluate effects of RYGB and LAGB on fasting and postprandial indices of bone remodeling. DESIGN AND SETTING: Ancillary investigation of a prospective study at 2 academic institutions. PARTICIPANTS: Obese adults aged 21-65 years with type 2 diabetes who underwent RYGB (n = 11) or LAGB (n = 8). OUTCOMES: Serum C-terminal telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP), and PTH were measured during a mixed meal tolerance test at baseline, 10 days and 1 year after surgery. Changes in 25-hydroxyvitamin D, polypeptide YY (PYY), glucagon-like peptide-1, glucose-dependent insulinotropic peptide, and insulin were also assessed. RESULTS: Fasting CTX increased 10 days after RYGB but not LAGB (+69 ± 23% vs +12±12%, P < .001), despite comparable weight loss at that time. By 1 year, fasting CTX and P1NP increased more after RYGB than LAGB (CTX +221 ± 60% vs +15 ± 6%, P<0.001; P1NP +93 ± 25% vs -9 ± 10%, P < .001) and weight loss was greater with RYGB. Changes in CTX were independent of PTH and 25-hydroxyvitamin D but were associated with increases in fasting PYY. Postprandial suppression of CTX was more pronounced after RYGB than LAGB at 10 days and 1 year postoperatively. CONCLUSIONS: RYGB is accompanied by early increases in fasting indices of bone remodeling, independent of weight loss or changes in PTH or 25-hydroxyvitamin D. LAGB did not affect bone markers. PYY and other enterohormonal signals may play a role in RYGB-specific skeletal changes.
Authors: Kerstin Stemmer; Maximilian Bielohuby; Bernadette E Grayson; Denovan P Begg; Adam P Chambers; Christina Neff; Stephen C Woods; Reinhold G Erben; Matthias H Tschöp; Martin Bidlingmaier; Thomas L Clemens; Randy J Seeley Journal: Endocrinology Date: 2013-04-03 Impact factor: 4.736
Authors: Christian Muschitz; Roland Kocijan; Christina Marterer; Arastoo Rahbar Nia; Gabriela Katharina Muschitz; Heinrich Resch; Peter Pietschmann Journal: J Clin Endocrinol Metab Date: 2014-12-09 Impact factor: 5.958
Authors: Arief Lalmohamed; Frank de Vries; Marloes T Bazelier; Alun Cooper; Tjeerd-Pieter van Staa; Cyrus Cooper; Nicholas C Harvey Journal: BMJ Date: 2012-08-03
Authors: Fernando Guerrero-Pérez; Anna Casajoana; Carmen Gómez-Vaquero; Nuria Virgili; Rafael López-Urdiales; Laura Hernández-Montoliu; Jordi Pujol-Gebelli; Javier Osorio; Carolina Alves; Manuel Perez-Maraver; Silvia Pellitero; Anna Vidal-Alabró; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa Journal: Obes Surg Date: 2020-01 Impact factor: 4.129
Authors: Anne L Schafer; Galateia J Kazakia; Eric Vittinghoff; Lygia Stewart; Stanley J Rogers; Tiffany Y Kim; Jonathan T Carter; Andrew M Posselt; Courtney Pasco; Dolores M Shoback; Dennis M Black Journal: J Bone Miner Res Date: 2018-02-05 Impact factor: 6.741
Authors: Tiffany Y Kim; Dolores M Shoback; Dennis M Black; Stanley J Rogers; Lygia Stewart; Jonathan T Carter; Andrew M Posselt; Nicole J King; Anne L Schafer Journal: Bone Date: 2019-11-02 Impact factor: 4.398